# Javier Naval

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8213554/publications.pdf

Version: 2024-02-01

| 41 | 2,233 | 218677 | 276875 |
|---|---|---|---|
| papers | citations | 26 h-index | 41 g-index |

| 42 | 42 | 42 | 3317 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma. Cells, 2022, 11, 392. | 4.1 | 7 |
| 2 | Future prospects for mitosis-targeted antitumor therapies. Biochemical Pharmacology, 2021, 190, 114655. | 4.4 | 24 |
| 3 | Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients. OncoImmunology, 2021, 10, 1853314. | 4.6 | 24 |
| 4 | Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance. Scientific Reports, 2020, 10, 19398. | 3.3 | 23 |
| 5 | Novel Forms of Immunomodulation for Cancer Therapy. Trends in Cancer, 2020, 6, 518-532. | 7.4 | 17 |
| 6 | Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Frontiers in Cell and Developmental Biology, 2019, 7, 50. | 3.7 | 139 |
| 7 | Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy. Cancers, 2019, 11, 444. | 3.7 | 37 |
| 8 | Role of Exosomes in the Regulation of T-cell Mediated Immune Responses and in Autoimmune Disease. Cells, 2019, 8, 154. | 4.1 | 121 |
| 9 | Response: Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Frontiers in Cell and Developmental Biology, 2019, 7, 306. | 3.7 | 4 |
| 10 | Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo. Cancer Letters, 2016, 382, 1-10. | 7.2 | 74 |
| 11 | Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein. Oncotarget, 2016, 7, 29287-29305. | 1.8 | 45 |
| 12 | MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells. OncoImmunology, 2015, 4, e985924. | 4.6 | 48 |
| 13 | In vivopotential of recombinant granulysin against human tumors. OncoImmunology, 2015, 4, e1036213. | 4.6 | 15 |
| 14 | Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis. Clinical and Translational Oncology, 2015, 17, 121-132. | 2.4 | 21 |
| 15 | IFNÎ± signaling through PKC-Î¸ is essential for antitumor NK cell function. OncoImmunology, 2014, 3, e948705. | 4.6 | 10 |
| 16 | Granulysin induces apoptotic cell death and cleavage of the autophagy regulator Atg5 in human hematological tumors. Biochemical Pharmacology, 2014, 87, 410-423. | 4.4 | 29 |
| 17 | Liposomes Decorated with Apo2L/TRAIL Overcome Chemoresistance of Human Hematologic Tumor Cells. Molecular Pharmaceutics, 2013, 10, 893-904. | 4.6 | 70 |
| 18 | Direct Interaction of Bax and Bak Proteins with Bcl-2 Homology Domain 3 (BH3)-only Proteins in Living Cells Revealed by Fluorescence Complementation. Journal of Biological Chemistry, 2013, 288, 4935-4946. | 3.4 | 74 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer. Biochemical Pharmacology, 2012, 83, 1475-1483. | 4.4 | 45 |
| 20 | Bortezomib resistance in a myeloma cell line is associated to PSMÎ²5 overexpression and polyploidy. Leukemia Research, 2012, 36, 212-218. | 0.8 | 75 |
| 21 | Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by rapamycin in human myeloma cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 311-322. | 4.1 | 19 |
| 22 | Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells. Biochemical Pharmacology, 2010, 79, 1746-1758. | 4.4 | 26 |
| 23 | Liposomeâ€bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis and Rheumatism, 2010, 62, 2272-2282. | 6.7 | 84 |
| 24 | Granzyme B of cytotoxic T cells induces extramitochondrial reactive oxygen species production via caspaseâ€dependent NADPH oxidase activation. Immunology and Cell Biology, 2010, 88, 545-554. | 2.3 | 21 |
| 25 | Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochemical Pharmacology, 2009, 77, 804-812. | 4.4 | 51 |
| 26 | Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes. Journal of Leukocyte Biology, 2008, 84, 488-498. | 3.3 | 17 |
| 27 | Mechanism of apoptosis induced by IFN-Î± in human myeloma cells: Role of Jak1 and Bim and potentiation by rapamycin. Cellular Signalling, 2007, 19, 844-854. | 3.6 | 38 |
| 28 | Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Experimental Cell Research, 2007, 313, 2378-2388. | 2.6 | 53 |
| 29 | Apo2L/TRAIL and immune regulation. Frontiers in Bioscience - Landmark, 2007, 12, 2074. | 3.0 | 34 |
| 30 | Human CD8+ Tâ€„cell blasts are more sensitive than CD4+ Tâ€„cell blasts to regulation by APO2L/TRAIL. European Journal of Immunology, 2005, 35, 1812-1821. | 2.9 | 27 |
| 31 | Farnesyltransferase Inhibitor BMS-214662 Induces Apoptosis in Myeloma Cells through PUMA Up-Regulation, Bax and Bak Activation, and Mcl-1 Elimination. Molecular Pharmacology, 2005, 67, 1991-1998. | 2.3 | 34 |
| 32 | Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-Î± in human myeloma cells. FEBS Letters, 2005, 579, 6217-6222. | 2.8 | 20 |
| 33 | Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. Journal of Cell Biology, 2004, 167, 457-468. | 5.2 | 121 |
| 34 | Differential Secretion of Fas Ligand- or APO2 Ligand/TNF-Related Apoptosis-Inducing Ligand-Carrying Microvesicles During Activation-Induced Death of Human T Cells. Journal of Immunology, 2001, 167, 6736-6744. | 0.8 | 240 |
| 35 | A Role of the Mitochondrial Apoptosis-Inducing Factor in Granulysin-Induced Apoptosis. Journal of Immunology, 2001, 167, 1222-1229. | 0.8 | 103 |
| 36 | CD59 cross-linking induces secretion of APO2 ligand in overactivated human T cells. European Journal of Immunology, 2000, 30, 1078-1087. | 2.9 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. European Journal of Immunology, 1998, 28, 2714-2725. | 2.9 | 179 |
| 38 | Doxorubicinâ€induced apoptosis in human Tâ€cell leukemia is mediated by caspaseâ€3 activation in a Fasâ€independent way. FEBS Letters, 1997, 417, 360-364. | 2.8 | 101 |
| 39 | CPP32 inhibition prevents Fas-induced ceramide generation and apoptosis in human cells. FEBS Letters, 1996, 390, 233-237. | 2.8 | 78 |
| 40 | Role of oxidative damage and IL-1Î²-converting enzyme-like proteases in Fas-based cytotoxicity exerted by effector T cells. International Immunology, 1996, 8, 1173-1183. | 4.0 | 24 |
| 41 | mtDNA-depleted U937 cells are sensitive to TNF and Fas-mediated cytototxicity. FEBS Letters, 1995, 376, 15-18. | 2.8 | 32 |